Pluri
Yahoo Finance • last year
Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
Results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS), currently under a $4.2 million contract with the U.S. National Institutes of Health PLX-R18 has the advantage of being an off-the-shelf product wi... Full story
Yahoo Finance • last year
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced... Full story
Yahoo Finance • last year
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome
Pluri's cell therapy is designed to be the first in class, effective treatment for ionizing radiation poisoning in the event of a large-scale nuclear incident. The work specified by the contractis based on communications with the FDA and w... Full story
Yahoo Finance • 2 years ago
Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products
Breakthrough systemsubstantially increases cell production,with the potential to reach much higher productivitydriven by platform’s significant scalability Flexible, industrial scale cell production to power a broad range of cell-based pro... Full story
Yahoo Finance • 2 years ago
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
HAIFA, Israel, March 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, announced today that Israel’s Ministry... Full story
Yahoo Finance • 2 years ago
Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
HAIFA, Israel, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, announced today that it has signed securities purchase agreements with domestic and non-... Full story
Yahoo Finance • 2 years ago
Pluri wins BioTech Breakthrough Cell Innovation of the Year Award
HAIFA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company” (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, won Cell Innovation award in the Cell Bi... Full story
Yahoo Finance • 2 years ago
Pluri to Present and Participate in Upcoming Conferences
HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”)(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced its participation in thr... Full story
Yahoo Finance • 2 years ago
€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri’s PLX-PAD Cells for Osteoarthritis Treatment
HAIFA, Israel, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced that a €7.5 million no... Full story
